Quantitative analysis of choroidal vasculature in polypoidal choroidal vasculopathy using ultra-widefield indocyanine green angiography

Sci Rep. 2020 Oct 26;10(1):18272. doi: 10.1038/s41598-020-75506-7.

Abstract

Polypoidal choroidal vasculopathy (PCV) is a common choroidal vascular disease particularly in Asians. However, the underlying pathogenesis of PCV is still yet to be fully elucidated, and the correlation between choroidal vasculature and treatment response of PCV are poorly understood. Accordingly, we sought to find clues to understand the pathogenesis and prognosis of PCV by quantitatively evaluating choroidal vasculature from the entire fundus using ultra-widefield (UWF) indocyanine green angiography (ICGA). In this study, 32 eyes from 29 patients with treatment naïve PCV and 30 eyes from 30 healthy control participants were enrolled. Choroidal vascular density (CVD) of PCV eyes was higher than normal eyes in majority regions including the periphery. CVD was positively correlated with choroidal thickness and choroidal hyperpermeability, supporting that the pathogenesis of PCV may include choroidal congestion and dilatation. Thicker choroid and higher CVD were also correlated with poor treatment response after anti-VEGF injections. The CVD, quantified from UWF ICGA can also be used as an effective image biomarker to predict the treatment response in PCV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Bevacizumab / therapeutic use
  • Case-Control Studies
  • Choroid Diseases / diagnosis*
  • Choroid Diseases / drug therapy
  • Female
  • Fluorescein Angiography
  • Humans
  • Indocyanine Green / administration & dosage*
  • Macular Degeneration / diagnosis*
  • Macular Degeneration / drug therapy
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / therapeutic use*
  • Ranibizumab / therapeutic use
  • Receptors, Vascular Endothelial Growth Factor / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • Treatment Outcome

Substances

  • Protein Kinase Inhibitors
  • Recombinant Fusion Proteins
  • aflibercept
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Indocyanine Green
  • Ranibizumab